导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.99% | 2942/4773 |
| 近一周 | -2.09% | 3370/5465 |
| 近一月 | -4.89% | 3504/5421 |
| 近一季 | -6.87% | 2581/5231 |
| 近半年 | -3.42% | 2478/4920 |
| 近一年 | 1.37% | 2505/4394 |
| 近两年 | 42.15% | 1809/2954 |
| 近三年 | 24.19% | 1333/2253 |
| 成立以来 | 106.45% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.35% 3152/4961 |
12.13% 2224/5312 |
- - |
- - |
| 2025 | 20.91% 2068/4813 |
0.01% 2012/3635 |
0.88% 2542/4076 |
19.98% 2063/4524 |
-0.10% 2360/4813 |
| 2024 | 13.46% 1136/3463 |
2.77% 710/2808 |
-1.07% 916/3014 |
15.68% 1653/3129 |
-3.53% 2360/3463 |
| 2023 | -10.90% 1346/2656 |
4.25% 1007/2280 |
-4.68% 1252/2385 |
-3.50% 944/2515 |
-7.09% 2046/2655 |
| 2022 | -19.63% 874/2207 |
-12.06% 567/1919 |
6.29% 729/2016 |
-14.80% 1149/2113 |
0.91% 1431/2208 |
| 2021 | -3.75% 927/1822 |
-0.99% 414/1255 |
1.43% 1053/1330 |
-5.78% 857/1466 |
1.71% 827/1822 |
| 2020 | 38.71% 351/1250 |
-9.16% 659/1028 |
12.35% 688/1067 |
16.69% 137/1164 |
16.46% 168/1184 |
| 2019 | 45.35% 152/1092 |
25.19% 475/754 |
3.26% 55/804 |
4.74% 185/850 |
7.35% 446/918 |
| 2018 | -17.97% 137/834 |
- - |
- - |
- - |
-11.37% 286/691 |
| 2017 | 28.91% 70/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.48% 197/605 |
- - |
- - |
- - |
- - |
| 2015 | -0.74% 259/575 |
- - |
- - |
- - |
- - |
| 2014 | 60.71% 32/237 |
- - |
- - |
- - |
- - |
| 2013 | -10.57% 157/186 |
- - |
- - |
- - |
- - |
| 2012 | 11.98% 26/140 |
- - |
- - |
- - |
- - |
| 2011 | -19.33% 30/102 |
- - |
- - |
- - |
- - |
| 2010 | -18.24% 48/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 海富通中证A100指数(LOF)A VS. 长安沪深300非周期A(740101) |